Evidence map›Paper›PMID 27107438›Full record

ArticleJournal of the American Medical Informatics Association : JAMIA2016

Automated identification of molecular effects of drugs (AIMED).

Safa Fathiamini, Amber M Johnson, Jia Zeng, Alejandro Araya, Vijaykumar Holla, Ann M Bailey, Beate C Litzenburger, Nora S Sanchez, Yekaterina Khotskaya, Hua Xu and 3 more

Abstract read
In one paragraph

Article in Journal of the American Medical Informatics Association : JAMIA, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. OncoCTMiner: streamlining precision oncology trial matching via molecular profile analysis.Database : the journal of biological databases and curation · 2023
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Exploring Novel Computable Knowledge in Structured Drug Product Labels.AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science · 2020
    Article
  10. OCTANE: Oncology Clinical Trial Annotation Engine.JCO clinical cancer informatics · 2019
    Article
  11. Article
  12. Article
  13. Article
  14. Precision medicine informatics.Journal of the American Medical Informatics Association : JAMIA · 2016
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Safa FathiaminiSchool of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.
Amber M JohnsonSheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Jia ZengSheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Alejandro ArayaSchool of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.
Vijaykumar HollaSheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Ann M BaileySheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Beate C LitzenburgerSheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Nora S SanchezSheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Yekaterina KhotskayaSheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Hua XuSchool of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA.
Funda Meric-BernstamSheikh Khalifa Al Nahyan Ben Zayed Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Elmer V BernstamSchool of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA Division of General Internal Medicine, Department of Internal Medicine, The University of Texas Health Science Center at Houston, TX, USA.
Trevor CohenSchool of Biomedical Informatics, The University of Texas Health Science Center at Houston, TX, USA trevor.cohen@uth.tmc.edu elmer.v.bernstam@uth.tmc.edu.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Informatics Tools for Pharmacogenomic Discovery using Practice-based DataR01GM103859 · NIGMS · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DENNY, JOSHUA C., PATHAK, JYOTISHMAN · 2014 to 2017
$2.4M
Informatics to enable routine personalized cancer therapyU01CA180964 · NCI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI BERNSTAM, ELMER V., MERIC-BERNSTAM, FUNDA · 2013 to 2015
$964k
NCI NIH HHS P30 CA016672NCI NIH HHS U01 CA180964NIGMS NIH HHS R01 GM103859
6 · The paper itself

Abstract

introductionGenomic profiling information is frequently available to oncologists, enabling targeted cancer therapy. Because clinically relevant information is rapidly emerging in the literature and elsewhere, there is a need for informatics technologies to support targeted therapies. To this end, we have developed a system for Automated Identification of Molecular Effects of Drugs, to help biomedical scientists curate this literature to facilitate decision support.

objectivesTo create an automated system to identify assertions in the literature concerning drugs targeting genes with therapeutic implications and characterize the challenges inherent in automating this process in rapidly evolving domains.

methodsWe used subject-predicate-object triples (semantic predications) and co-occurrence relations generated by applying the SemRep Natural Language Processing system to MEDLINE abstracts and ClinicalTrials.gov descriptions. We applied customized semantic queries to find drugs targeting genes of interest. The results were manually reviewed by a team of experts.

resultsCompared to a manually curated set of relationships, recall, precision, and F2 were 0.39, 0.21, and 0.33, respectively, which represents a 3- to 4-fold improvement over a publically available set of predications (SemMedDB) alone. Upon review of ostensibly false positive results, 26% were considered relevant additions to the reference set, and an additional 61% were considered to be relevant for review. Adding co-occurrence data improved results for drugs in early development, but not their better-established counterparts.

conclusionsPrecision medicine poses unique challenges for biomedical informatics systems that help domain experts find answers to their research questions. Further research is required to improve the performance of such systems, particularly for drugs in development.

Indexed as

Natural Language ProcessingPrecision MedicineAntineoplastic AgentsClinical Trials as TopicHumansInformation Storage and RetrievalMEDLINENeoplasmsSemanticsUnified Medical Language SystemAntineoplastic Agentsbiomedical question answeringmolecularpharmacogenomicsprecision oncologySemReptargeted therapy

Identifiers

PMID27107438
PMCPMC4926748

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.